Therefore, we perform a systematic review with the NMA of all randomized trials to compare short-term treatment efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab at the dosage level for moderate to severe plaque psoriasis. The gene discussed is IL23A; the disease is psoriasis vulgaris.